Related references
Note: Only part of the references are listed.A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
Tomoko Kobayashi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
Marina Tsoli et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee-Shing Chang et al.
ENDOCRINE REVIEWS (2019)
Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation
Sriram Gubbi et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
Isabella Lupi et al.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS (2019)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
S. Cuzzubbo et al.
EUROPEAN JOURNAL OF CANCER (2017)
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Ichiro Yamauchi et al.
THYROID (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
Elisa Gonzalez-Rodriguez et al.
ONCOLOGIST (2016)
Share Paper
